Correlation Between Soleno Therapeutics and Reviva Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Soleno Therapeutics and Reviva Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Soleno Therapeutics and Reviva Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Soleno Therapeutics and Reviva Pharmaceuticals Holdings, you can compare the effects of market volatilities on Soleno Therapeutics and Reviva Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Soleno Therapeutics with a short position of Reviva Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Soleno Therapeutics and Reviva Pharmaceuticals.

Diversification Opportunities for Soleno Therapeutics and Reviva Pharmaceuticals

-0.09
  Correlation Coefficient

Good diversification

The 3 months correlation between Soleno and Reviva is -0.09. Overlapping area represents the amount of risk that can be diversified away by holding Soleno Therapeutics and Reviva Pharmaceuticals Holding in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Reviva Pharmaceuticals and Soleno Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Soleno Therapeutics are associated (or correlated) with Reviva Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Reviva Pharmaceuticals has no effect on the direction of Soleno Therapeutics i.e., Soleno Therapeutics and Reviva Pharmaceuticals go up and down completely randomly.

Pair Corralation between Soleno Therapeutics and Reviva Pharmaceuticals

Given the investment horizon of 90 days Soleno Therapeutics is expected to generate 1.33 times less return on investment than Reviva Pharmaceuticals. But when comparing it to its historical volatility, Soleno Therapeutics is 1.98 times less risky than Reviva Pharmaceuticals. It trades about 0.07 of its potential returns per unit of risk. Reviva Pharmaceuticals Holdings is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  90.00  in Reviva Pharmaceuticals Holdings on August 30, 2024 and sell it today you would lose (67.00) from holding Reviva Pharmaceuticals Holdings or give up 74.44% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Soleno Therapeutics  vs.  Reviva Pharmaceuticals Holding

 Performance 
       Timeline  
Soleno Therapeutics 

Risk-Adjusted Performance

6 of 100

 
Weak
 
Strong
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Soleno Therapeutics are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Soleno Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.
Reviva Pharmaceuticals 

Risk-Adjusted Performance

11 of 100

 
Weak
 
Strong
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Reviva Pharmaceuticals Holdings are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent technical indicators, Reviva Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Soleno Therapeutics and Reviva Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Soleno Therapeutics and Reviva Pharmaceuticals

The main advantage of trading using opposite Soleno Therapeutics and Reviva Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Soleno Therapeutics position performs unexpectedly, Reviva Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Reviva Pharmaceuticals will offset losses from the drop in Reviva Pharmaceuticals' long position.
The idea behind Soleno Therapeutics and Reviva Pharmaceuticals Holdings pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Other Complementary Tools

Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Fundamental Analysis
View fundamental data based on most recent published financial statements